ELENZA

About ELENZA

Elenza, Inc. operates within the therapeutic devices sector, focusing on developing advanced solutions for vision correction. The company, originally founded as Ocular Optics, Inc. in 2008, is centered on addressing the multibillion-dollar intraocular lens (IOL) market. Its primary market includes patients undergoing cataract surgery and those seeking correction for presbyopia.

The company's core product is a patented Electro-active AutoFocal Intraocular Lens. This isn't a typical IOL; it incorporates a proprietary blend of chemistry, electricity, and integrated circuitry to create what the company terms "smart optics". The lens features an electro-active element that adjusts its focusing power electronically in milliseconds. This allows it to automatically shift focus for near, intermediate, and distance vision, mimicking the natural function of the eye. A key feature is its micro-sized power cell, engineered to have a rechargeable cycle life of over 50 years.

Initially based in Roanoke, Virginia, the company's foundational technology was licensed from PixelOptics, the creator of the first electronic focusing spectacles. Elenza successfully secured a Series A financing round in 2008 from investors including The Carlyle Group and Delphi Ventures. This was followed by a significant $24 million Series B financing in 2011, which brought in new investors such as Itochu Corporation, aimed at funding clinical development and securing regulatory approval in Europe. The leadership team included Rudy Mazzocchi as President and CEO, an experienced medical device entrepreneur, and Amitava Gupta, PhD, as Chief Technical Officer. According to PitchBook, Elenza, Inc. was acquired on November 6, 2014.